The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

(2020) Uta Schilling et al.   CLINICAL PHARMACOKINETICS

Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction

(2020) Peter Sinnaeve et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Absorption, distribution, metabolism, and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects

(2019) Mike Ufer et al.   XENOBIOTICA

Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects

(2018) Pierre-Eric Juif et al.   JOURNAL OF CLINICAL PHARMACOLOGY

2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction

(2016) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Management of Patients With NSTE-ACS

(2016) Fatima Rodriguez et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updates and Current Recommendations for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice

(2015) Guillaume Cayla et al.   AMERICAN JOURNAL OF CARDIOLOGY

4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

(2015) Eva Caroff et al.   JOURNAL OF MEDICINAL CHEMISTRY

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

(2014) Daniela Baldoni et al.   CLINICAL DRUG INVESTIGATION

Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12-receptor

(2014) K. Hoffmann et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation

(2013) L. Jiang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH

(2013) M. Cattaneo et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pharmacokinetic and Pharmacodynamic Effects of Elinogrel

(2012) Dominick J. Angiolillo et al.   Circulation-Cardiovascular Interventions

Extracellular Ca2+ modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation

(2011) Sarah Jones et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

(2011) J. J. J. van Giezen et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Historical perspective and future directions in platelet research

(2011) B. S. COLLER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Platelet function testing in hirudin and BAPA anticoagulated blood

(2010) Helen Mani et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests

(2009) C. A. C. M. PITTENS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ticagrelor binds to human P2Y12independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation

(2009) J. J. J. VAN GIEZEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities

(2008) A. L. FRELINGER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin

(2008) H. J. BOUMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS